ERBB2 and breast carcinoma: In a retrospective study with patients affected by HER2-positive breast cancer that developed BM, Nam and colleagues reported a median OS of 13 months in patients who received trastuzumab compared with 4 months in those who did not receive trastuzumab and 3 months in patients with HER2-negative tumors [113].